www.lesswrong.com/posts/vHSkxmYYqW59sySqA/the-likely-first-longevity-drug-is-bas...

The claim that Loyal had "zero publications" is contradicted by multiple peer-reviewed papers published before this LessWrong post on December 12, 2023.

For example:

1. In 2022, a Loyal-affiliated paper in Frontiers in Veterinary Science proposed a "conceptual framework for aging in dogs" and said it would facilitate the development and testing of interventions to prolong healthspan and lifespan in dogs by directly targeting the biological mechanisms of aging.

2. In February 2023, a Loyal-affiliated paper in GeroScience studied frailty and quality-of-life tools in 451 companion dogs and explained that such tools are important for evaluating gerotherapeutics and advancing canine longevity research.

So while one could argue Loyal had disclosed less product-specific detail than some readers wanted, it is factually wrong to say the company had published zero material. There were already peer-reviewed Loyal-affiliated publications on canine aging and longevity-related research before this post was published.